Effects of KS-501, KS-502 and their enantiomers on calmodulin-sensitive enzyme activity and cellular proliferation
Related Experiment Videos
W N Hait1, J Gesmonde, E Cheng
1Yale University School of Medicine, Department of Medicine, New Haven, CT 06510, USA.
Abstract:
Calmodulin plays an important role in cellular proliferation as part of a signal transduction pathway activated by phospholipase C. Drugs that block the ability of calmodulin to bind to and activate its target enzymes inhibit the growth of a wide variety of malignant cells. To identify more potent and selective inhibitors of this potential target for new drug development, we studied two recently synthesized compounds, KS-501 and KS-502, for their activity against calmodulin-sensitive enzymes and for their ability to block the growth of parental and multidrug-resistant leukemic cells. KS-501 and KS-502 inhibited the activation of a calmodulin-sensitive cyclic nucleotide phosphodiesterase. The mechanism of enzyme inhibition was through interfering with calmodulin activation rather than through a direct effect on the enzyme. KS-501 was more potent than KS-502 and was studied in greater detail. This compound inhibited the activation of calmodulin kinase I and II, but had less effect against cyclic adenosine 3',5'-monophosphate (cyclic AMP)-sensitive kinase. KS-501 was also more effective than KS-502 in inhibiting the growth of sensitive L1210 leukemic lymphocytes. Both compounds were less effective inhibitors of multidrug-resistant L1210 leukemia than of the parental line. These studies identify a new class of calmodulin inhibitor, with selectivity for calmodulin-dependent kinases over cyclic AMP-dependent protein kinase. Since the total synthesis of the KS-compounds has been accomplished, it should now be possible to develop derivatives with greater activity and selectivity.
Insights
New compounds KS-501 and KS-502 inhibit calmodulin activation, blocking leukemic cell growth. KS-501 shows greater potency and selectivity for calmodulin-dependent kinases, offering a promising avenue for novel cancer drug development.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Calmodulin is crucial for cellular proliferation via signal transduction pathways.
- Inhibiting calmodulin's enzyme interactions can impede malignant cell growth.
- Developing potent and selective calmodulin inhibitors is key for new cancer therapeutics.
Purpose of the Study:
- To evaluate novel compounds KS-501 and KS-502 as calmodulin inhibitors.
- To assess their efficacy against calmodulin-sensitive enzymes and leukemic cell lines.
- To explore their potential as anticancer drugs.
Main Methods:
- Assessed KS-501 and KS-502 for inhibition of calmodulin-sensitive cyclic nucleotide phosphodiesterase.
- Investigated the mechanism of enzyme inhibition (calmodulin activation interference).
- Tested compound activity against calmodulin kinase I, II, and cyclic AMP-sensitive kinase, and leukemic cell growth.
Main Results:
- KS-501 and KS-502 effectively inhibited calmodulin-sensitive phosphodiesterase by interfering with calmodulin activation.
- KS-501 demonstrated higher potency than KS-502 and inhibited calmodulin kinase I and II.
- Both compounds inhibited sensitive L1210 leukemic cell growth, but were less effective against multidrug-resistant lines.
Conclusions:
- Identified KS-501 and KS-502 as a new class of calmodulin inhibitors.
- Demonstrated selectivity for calmodulin-dependent kinases over cyclic AMP-dependent protein kinase.
- The established synthesis of KS-compounds allows for future development of enhanced derivatives for cancer therapy.